Contents

Search


ospemifene (Osphena)

Indications: - moderate-to-severe dyspareunia - painful intercourse due to vulvar & vaginal atrophy during menopause - moderate to severe genitourinary syndrome of menopause Contraindications: - abnormal vaginal bleeding - pregnancy - history of thromboembolism, stroke, or myocardial infarction - history of breast cancer, ovarian cancer, uterine cancer Dosage: - 60 mg PO QD - take with food Tabs: 60 mg film-coated tablets Storage: store at room temperature Pharmacokinetics: - highly protein-bound - metabolized by CYP3A4 & CYP2C9, & to a small extent, CYP2C19 [3] Adverse effects: - thickening of the endometrium - vaginal discharge, vaginal bleeding - hot flashes - muscle spasms - excessive sweating - risks for stroke & deep venous thrombosis are reportedly less than with estrogen therapy Drug interactions: - CYP3A4 inhibitors may increase ospemifene levels - fluconazole can increase ospemifene levels 3-fold - smaller increases in ospemifene levels occur with ketoconazole & omeprazole - CYP3A4 inducers may decrease ospemifene levels - rifampin can decrease ospemifene levels by ~60% [3] Mechanism of action: - selective estrogen receptor modulator - estrogen receptor agonist/antagonist Notes: - wholesale average cost (2014) is about $160 for a month supply [3]

General

selective estrogen receptor modulator (SERM)

Database Correlations

PUBCHEM correlations

References

  1. FDA News Release: Feb. 26, 2013 FDA approves Osphena for postmenopausal women experiencing pain during sex. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm341128.htm
  2. Rutanen EM, Heikkinen J, Halonen K et al Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003 Sep-Oct;10(5):433-9 PMID: 14501605
  3. Prescriber's Letter 21(3): 2014 Postmenopausal Hormone Therapy CHART: Postmenopausal Hormone Therapy COMMENTARY: Nonhormonal Therapy for Hot Flashes COMMENTARY: New Drug: Osphena (Ospemifene) SPECIAL REPORT: Natural Medicines in the Clinical Management of Menopausal Symptoms Detail-Document#: 300310 (subscription needed) http://www.prescribersletter.com
  4. Geriatric Review Syllabus, 9th edition (GRS9) Medinal-Walpole A, Pacala JT, Porter JF (eds) American Geriatrics Society, 2016 - Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022